Zydus Lifesciences Ltd

Company Profile

Zydus Lifesciences Ltd had its IPO on under the ticker symbol CADILAHC.

The company operates in the sector and industry. Zydus Lifesciences Ltd has a staff strength of 0 employees.

Stock update

Shares of Zydus Lifesciences Ltd opened at ₹521.05 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹521.05 - ₹528.5, and closed at ₹525.35.

This is a +0.12% increase from the previous day's closing price.

A total volume of 18,293 shares were traded at the close of the day’s session.

In the last one week, shares of Zydus Lifesciences Ltd have increased by +1.73%.

Zydus Lifesciences Ltd's Key Ratios

Zydus Lifesciences Ltd has a market cap of ₹354.57 billion, indicating a price to book ratio of 2.2535 and a price to sales ratio of 2.3763.

In the last 12-months Zydus Lifesciences Ltd’s revenue was ₹0 with a gross profit of ₹91.73 billion and an EBITDA of ₹0. The EBITDA ratio measures Zydus Lifesciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zydus Lifesciences Ltd’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q3.6666666666667, Zydus Lifesciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Zydus Lifesciences Ltd’s PE and PEG Ratio

Forward PE

20.202

Trailing PE

26.7369

PEG

Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 20.202 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zydus Lifesciences Ltd’s profitability.

Zydus Lifesciences Ltd stock is trading at a EV to sales ratio of 2.3907 and a EV to EBITDA ratio of 10.6384. Its price to sales ratio in the trailing 12-months stood at 2.3763.

Zydus Lifesciences Ltd stock pays annual dividends of ₹3.5 per share, indicating a yield of 1% and a payout ratio of 8.76%.

Balance sheet and cash flow metrics

Total Assets

₹0

Total Liabilities

₹0

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

8.76%

Zydus Lifesciences Ltd ended 1970 with ₹0 in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹0 while shareholder equity stood at ₹0.

Zydus Lifesciences Ltd ended 1970 with ₹0 in deferred long-term liabilities, ₹0 in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

Zydus Lifesciences Ltd’s total current assets stands at ₹0 while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹0 compared to accounts payable of ₹0 and inventory worth ₹0.

In 1970, Zydus Lifesciences Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Zydus Lifesciences Ltd paid ₹0.09 in dividends in 1970.

Other key metrics

Current Trading Price

₹525.35

52-Week High

₹530.7

52-Week Low

₹350.3

Analyst Target Price

₹

Zydus Lifesciences Ltd stock is currently trading at ₹525.35 per share. It touched a 52-week high of ₹530.7 and a 52-week low of ₹530.7. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹359.17 and 200-day moving average was ₹466.8 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.